Diabetic Support Protocol

Overview

Type 2 diabetes is a progressive disease of insulin resistance and eventual beta-cell dysfunction. Modern incretin-based pharmacotherapy — Semaglutide and Tirzepatide in particular — has transformed what is achievable in terms of weight loss, glycemic control, and cardiovascular risk reduction. This protocol organizes the use of these tools alongside lifestyle interventions and monitoring for adults with, or at high risk of, type 2 diabetes.

The protocol is explicitly adjunctive to physician-directed care. GLP-1 and dual agonist drugs are prescription medications in most jurisdictions and require appropriate medical management, especially when layered onto existing insulin, sulfonylureas, or SGLT2 inhibitors.

Compounds Involved

Semaglutide / Tirzepatide

Incretin-based therapy addresses multiple diabetes pathophysiologic defects at once: appetite regulation, gastric emptying, glucagon suppression, and glucose-dependent insulin release. Cardiovascular outcome trials (SUSTAIN-6, SURPASS, etc.) have demonstrated meaningful event reduction in appropriate patients.

Metformin

Metformin remains first-line pharmacotherapy in most guidelines due to efficacy, tolerability, and decades of safety data. It is commonly continued alongside incretin therapy.

Berberine

Berberine has modest glycemic effects through AMPK activation. It is a reasonable adjunct for patients who cannot access or tolerate incretin therapy, but it is not equivalent to a GLP-1.

Protocol Structure

Phase 1 — Assessment and Foundation (Weeks 1–4)

• Baseline labs — HbA1c, fasting glucose, CMP (with renal function), lipid panel, urinary albumin/creatinine, TSH, vitamin D, B12
• Cardiovascular risk — calculate 10-year ASCVD risk; consider CAC score; discuss statin/antihypertensive therapy with clinician
• Nutrition — reduce refined carbohydrate and ultra-processed intake; emphasize whole foods, fiber, lean protein; continuous glucose monitoring for 2 weeks is extremely informative
• Training — 150 minutes/week aerobic, 2–3 resistance sessions. Walking after meals meaningfully improves post-prandial glucose.
• Sleep — treat sleep apnea if present; 7–9 hours consistent schedule

Phase 2 — Pharmacologic Initiation (Weeks 4–16)

In partnership with a clinician:

• Metformin 500 mg with evening meal, titrate to 1000 mg BID as tolerated
• Semaglutide start 0.25 mg weekly × 4, then 0.5 mg × 4, then escalate per response
  • Alternative: Tirzepatide 2.5 mg weekly × 4, then 5 mg × 4, escalate per response
• Adjust other hypoglycemic agents — insulin and sulfonylurea doses must be reduced proactively to avoid hypoglycemia
• Consider SGLT2 inhibitor for cardiorenal benefit per clinician judgment

Phase 3 — Optimization (Months 4–12)

• Titrate Semaglutide to 1.0–2.0 mg weekly (or Tirzepatide to 10–15 mg weekly) per HbA1c response and tolerability
• Target HbA1c individualized — often <7.0%, sometimes <6.5% in younger patients without hypoglycemia risk
• Quarterly HbA1c, annual urinary albumin, lipid panel, renal function
• Maintain aerobic and resistance training; continue dietary discipline
• Lean mass preservation with adequate protein (1.6–2.0 g/kg goal weight)

Phase 4 — Long-Term Maintenance

• Incretin therapy is typically indefinite; discontinuation often produces weight and glycemic regain
• Continue lifestyle foundations; retinal exam annually, foot exam routinely
• Adjust pharmacotherapy as glycemic status evolves — type 2 diabetes is progressive even with good control

Important Considerations

• GLP-1 and dual agonists carry a boxed warning for medullary thyroid carcinoma and are contraindicated in MEN2 and in personal/family history of MTC.
• Hypoglycemia risk is primarily driven by concurrent insulin or sulfonylurea therapy; proactive dose reduction is essential.
• Gastrointestinal side effects (nausea, constipation, early satiety) are the dominant tolerability issue; slow titration and hydration help.
• Pancreatitis is a recognized rare complication — severe epigastric pain requires urgent evaluation.
• Gallbladder disease is more common with rapid weight loss and with incretin therapy.
• Diabetic retinopathy can transiently worsen with rapid glycemic improvement; retinal evaluation before and during therapy is appropriate in established retinopathy.
• Renal dosing adjustments apply to metformin and SGLT2 inhibitors; coordinate with clinician.
• Type 1 diabetes is not the target population for this protocol; incretin therapy in T1DM is specialist-only.
• Lean mass loss is a concern during rapid weight reduction; protein intake and resistance training are mandatory.

Disclaimer

This content is for educational and informational purposes only and is not medical advice. Type 2 diabetes is a chronic disease requiring ongoing medical evaluation and management. Semaglutide, Tirzepatide, Metformin, and SGLT2 inhibitors are prescription medications and must be obtained and managed through appropriate clinical channels. Do not modify prescribed diabetes medications without consulting your clinician. Pepperpedia does not endorse the acquisition or use of prescription medications outside of legitimate medical channels.